Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P, Koopman B, Kok K, Ter Elst A, Schuuring E, van Kempen LC, Timens W, Hiltermann TJN, Groen HJM, van den Berg A, van der Wekken AJ. Meng P, et al. Among authors: koopman b. Lung Cancer. 2020 Aug;146:358-361. doi: 10.1016/j.lungcan.2020.05.036. Epub 2020 Jun 4. Lung Cancer. 2020. PMID: 32534795 Free article.
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.
Koopman B, Groen HJM, Schuuring E, Hiltermann TJN, Timens W, den Dunnen WFA, van den Berg A, Ter Elst A, van Kruchten M, Kluiver JL, Hiddinga BI, Hijmering-Kappelle LBM, Groves MR, Vilacha JF, van Kempen LC, van der Wekken AJ. Koopman B, et al. Clin Lung Cancer. 2022 Mar;23(2):e104-e115. doi: 10.1016/j.cllc.2021.06.011. Epub 2021 Jul 3. Clin Lung Cancer. 2022. PMID: 34325996 Free article. Review.
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles.
Koopman B, van der Wekken AJ, Ter Elst A, Hiltermann TJN, Vilacha JF, Groves MR, van den Berg A, Hiddinga BI, Hijmering-Kappelle LBM, Stigt JA, Timens W, Groen HJM, Schuuring E, van Kempen LC. Koopman B, et al. JCO Precis Oncol. 2020 Nov;4:393-410. doi: 10.1200/PO.20.00008. JCO Precis Oncol. 2020. PMID: 35050740
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
Koopman B, Groen HJM, Ligtenberg MJL, Grünberg K, Monkhorst K, de Langen AJ, Boelens MC, Paats MS, von der Thüsen JH, Dinjens WNM, Solleveld N, van Wezel T, Gelderblom H, Hendriks LE, Speel EM, Theunissen TE, Kroeze LI, Mehra N, Piet B, van der Wekken AJ, Ter Elst A, Timens W, Willems SM, Meijers RWJ, de Leng WWJ, van Lindert ASR, Radonic T, Hashemi SMS, Heideman DAM, Schuuring E, van Kempen LC. Koopman B, et al. Oncologist. 2021 Aug;26(8):e1347-e1358. doi: 10.1002/onco.13580. Epub 2020 Nov 10. Oncologist. 2021. PMID: 33111480 Free PMC article.
Non-small-cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy.
Koopman B, Hiddinga BI, Platteel I, Kluiver JL, Timens W, Mulder AB, van Doesum JA, Schuuring E, Diepstra A, van Kempen LC. Koopman B, et al. Histopathology. 2021 Jun;78(7):1043-1046. doi: 10.1111/his.14326. Epub 2021 Apr 3. Histopathology. 2021. PMID: 33410163 Free PMC article. No abstract available.
Association of homozygous variants of STING1 with outcome in human cervical cancer.
Lubbers JM, Koopman B, de Klerk-Sluis JM, van Rooij N, Plat A, Pijper H, Koopman T, van Hemel BM, Hollema H, Wisman B, Nijman HW, de Bruyn M. Lubbers JM, et al. Among authors: koopman t, koopman b. Cancer Sci. 2021 Jan;112(1):61-71. doi: 10.1111/cas.14680. Epub 2020 Nov 20. Cancer Sci. 2021. PMID: 33040406 Free PMC article.
188 results